The first cancer for which differentiation therapy was demonstrated as a viable approach was acute promyelocytic leukemia (APL), a sub‐type of AML commonly driven by the t(15;17) chromosomal translocation encoding the PML‐RARα fusion protein. The gene discussed is RARA; the disease is acute promyelocytic leukemia.